

Cross-sectoral roundtable

Tackling anti-microbial resistance (AMR)

26 March 2020, 16.00-18.30

Croatian Academy of Sciences and Arts



The cross-sectoral roundtable is organized by the *FEAM European Biomedical Policy Forum* - in collaboration with the *Croatian Academy of Sciences and Arts* - and hosted by the *Croatian Academy of Medical Sciences*, under the auspices of the Croatian Presidency of the Council of the European Union.

Participation is by invitation only.

Programme of the Meeting

Chair | George Griffin, President of the Federation of European Academies of Medicine (FEAM)

16.00-16.10	<i>Welcome and opening remarks</i>
16.10-16.30	The challenge of antimicrobial resistance Dr Susan Hopkins, Public Health England (TBC)
16.30-16.45	Tackling AMR: the Croatian experience Professor Arjana Tambić Andrašević, Professor of Clinical Microbiology at Zagreb University Hospital for Infectious Diseases, "Dr. Fran Mihaljević", Zagreb, Croatia
16.45-17.00	Emerging and re-emerging infectious diseases - a continuous biothreat Professor Alemka Markotić, Director, University hospital for infectious diseases "Dr. Fran Mihaljević", Zagreb, full professor at the Faculty of medicine, University of Rijeka, Associate member of the Croatian Academy of Sciences and Arts
17.00-17.15	The role of pharmaceutical industry in developing new antibiotics Dr Aleksandar Danilovski, Chief Scientific Officer and Senior Vice President Global R&D and Regulatory Affairs, Xellia Pharmaceuticals
17.15-17.30	<i>Discussion</i>
17.30-18.15	<i>Panel discussion: Multi-sectoral collaboration to address AMR</i>
	<ul style="list-style-type: none">• John Ryan, Deputy Director General, DG SANTE, European Commission• Vera Katalinić-Janković, Croatian Assistant Minister of Health• Arjana Tambić Andrašević, Zagreb University Hospital for Infectious Diseases• Dominique Monnet, European Centre for Disease Prevention and Control• Aleksandar Danilovski, Xellia Pharmaceuticals• Andre Jestin, French Veterinary Academy• Claudie Charbonneau, Global Team Lead Patient & Health Impact - Pfizer
18.15-18.30	<i>Discussion</i>

Federation of European Academies of Medicine (FEAM)

<https://www.feam.eu/>

Croatian Academy of Medical Sciences

<http://www.amzh.hr/>

Croatian Academy of Sciences and Arts

http://info.hazu.hr/en/about_academy/foundation_of_academy/

About the workshop

Background

Anti-microbial resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi or parasites adapt in order to get resistant to medications normally used to cure infections. When the microorganisms become resistant to most antimicrobials they are often referred to as “superbugs”. Nowadays, this is a major concern since a resistant strain could lead to infection that may spread and kill the host, inducing huge costs to individuals and society.

AMR occurs naturally but is facilitated by the inappropriate use of medicines and antibiotics, by wrong prescriptions and by the poor infection prevention. All these factors encourage the development and the spread of drug resistance, therefore government commitment, strong surveillance, improved tools for diagnosis, treatment and prevention are mandatory to control the transmission of drug resistance.

For all these reasons, the Federation of European Academies of Medicine (FEAM), the Croatian Academy of Medical Sciences and the FEAM European Biomedical Policy Forum are organizing a closed roundtable discussion with the objective to provide European countries with support and recommendations to implement efficient and cost-effective policies to tackle AMR, by promoting the correct use of antimicrobials and encouraging research and development of new solutions for the one of the biggest public health challenges of our time.

About the FEAM European Biomedical Policy Forum

The FEAM European Biomedical Policy Forum provides a platform for discussion on key policy issues for the biomedical community. The Forum is an initiative from the Federation of European Academies of Medicine (FEAM). It aims to bring together representatives from academia, research charities, industry, European and national trade associations and professional bodies, regulators, public health bodies, and patient and consumers groups. Partners join on an equal footing, regardless of size and type of organisation.